Pharmacological properties
Interferon alpha-2b recombinant has a pronounced antiviral, antiproliferative and immunomodulatory effect. the complex composition of laferobion causes a number of new effects: in combination with tocopherol acetate and ascorbic acid, the antiviral activity of recombinant interferon alpha-2b increases 10–14 times, its immunomodulatory effect on T- and B-lymphocytes is enhanced, the content of immunoglobulin is normalized, e. antibodies are not formed , neutralizing the antiviral activity of recombinant interferon alpha-2b, even when using interferon for 2 years, the functioning of the endogenous system is normalized.
Laferobion nasal spray. 100 thousand IU/ml 5ml bottle - Instructions
Compound
The main active substance is recombinant human interferon alpha-2b.
Other components are presented in the form of trometamol, trometamol hydrochloride, hypromellose, sodium edetate, lysine hydrochloride, potassium chloride, methyl parahydroxybenzoate (E 218), water for injection.
Release form
The drug is in the form of a spray for nasal use. Supplied in 5 ml bottles.
pharmachologic effect
After injection of the drug, the interferon contained in the composition will react with specific receptors on the cell wall and activate a cascade of events: production of intracellular protein, inhibition of cell proliferation, stimulation of phagocytic activity of macrophages and activity of lymphocytes towards target cells, suppression of viral replication in infected cells .
Pharmacokinetics
Data not provided.
Indications for use
The drug is used as a component of therapy for the prevention of acute respiratory viral infections.
Contraindications
Strict restrictions include:
- allergy to interferon alpha or other ingredients;
- autoimmune hepatitis;
- decompensated liver disease;
- history of hemoglobinopathy.
Side effects
The composition is well tolerated and has virtually no negative effects. Only in rare cases is an allergic reaction due to intolerance possible.
Compatibility with other medications
No interaction studies have been conducted.
Application and dosage
The drug is administered intranasally.
At the first signs of ARVI (within 5 days):
Adults should administer 3 sprays into each nasal passage 5-6 times a day.
Children aged 1 to 3 years - 2 injections into each nasal passage 3-4 times a day.
Children 3-14 years old - 2 injections into each nasal passage 4-5 times a day.
Children aged 14 to 18 years: spray into each nasal passage 5-6 times a day.
In case of contact with a patient and in case of hypothermia - 3 injections 2 times a day for 5-7 days.
If necessary, preventive courses are repeated. For single contact, a single application is sufficient.
When there is a seasonal increase in incidence - once in the morning with an interval of 1-2 days.
Overdose
To date, no cases of overdose have been reported.
special instructions
In order to avoid the spread of infection, individual use of the bottle is recommended.
Use during pregnancy and breastfeeding
The use of Laferobion is not recommended.
Impact on the ability to drive vehicles and operate machinery
No special precautions are required.
Terms of sale
Over the counter.
Storage conditions
In a dry, cool place, with limited access for children.
Application
For children: in complex therapy of ARVI, the recommended doses are:
For newborns and premature babies, the drug is prescribed 150,000 IU, 2 suppositories per day with a 12-hour interval. Courses of treatment and breaks between courses are 5 days.
For premature newborns with a gestational age of less than 34 weeks, prescribe the drug 150,000 IU 3 times a day (every 8 hours) rectally. The course is 5 days.
Children aged 1 to 7 years - 500,000 IU 2 times a day.
Children aged 7–14 years - 1,000,000 IU 2 times a day for 5 days.
Instructions for use of Laferobion and dose
Laferobion suppositories are used rectally. Usually the course of treatment is 10 days. For papillomavirus infection, precancerous diseases of the cervix, bacterial, viral and mixed infections and urogenital mixed infections, sexually transmitted infections, one Laferobion 1.5 million IU suppository is usually prescribed every 12 hours.
Children are prescribed Laferobion as part of complex therapy, one Laferobion suppository 150 thousand IU every 12 hours. The average course duration is 5 days. When treating ARVI, pneumonia of various etiologies and meningitis, one course is usually sufficient. To treat infections caused by the Epstein-Barr virus, an increase in dosage and course duration is required.
Laferobion solution in ampoules is used intramuscularly, intravenously, intradermally, subcutaneously, intravesically, intraperitoneally, rectally and intranasally, subconjunctivally.
When treating ARVI in children, Laferobion 100,000 IU/ml is used intranasally, 4–6 drops in each nasal passage up to 6 times a day for 3–5 days; for newborns, Laferobion is used at 20,000–50,000 IU/ml. You can also use cotton pads soaked in Laferobion solution in ampoules up to 8 times a day.
In the treatment of acute intestinal infections in children, Laferobion is used rectally at a dose of 10,000 IU/kg. In the treatment of peritonitis, purulent-septic diseases, multiple abscesses of the abdominal cavity, Laferobion is used in ampoules intravenously at 2–4 million ME once a day, but not more than 12–16 million ME per course.
Treatment of children with Laferobion for other diseases is determined individually by the doctor, depending on the age and course of the disease.
Contraindications
Hypersensitivity to the components of the drug; the patient has thyroid dysfunction; the presence of severe visceral disorders in patients with Kaposi's sarcoma; severe cardiovascular diseases; psoriasis; severe dysfunction of the liver and/or kidneys; epilepsy and other diseases of the central nervous system (including functional ones); chronic hepatitis against the background of progressive or decompensated cirrhosis of the liver; chronic hepatitis in patients receiving or recently receiving immunosuppressant therapy (except for a short course of corticosteroid therapy); history of autoimmune hepatitis or other autoimmune diseases. inhibition of the myeloid lineage of hematopoiesis.
Indications for use of Laferobion
According to the instructions, Laferobion is used as part of complex therapy for infections caused by:
- Hepatitis B virus, in severe and moderate forms;
- Mixed infections, viral or bacterial, including in infants under 1 month;
- Herpes virus, including herpetic eye lesions, herpetic skin rashes, genital herpes, herpes zoster;
- Human papillomavirus.
Laferobion is also used as part of complex therapy for multiple sclerosis and cancer:
- Tumors of various locations, including bladder, ovarian, kidney, and breast cancer;
- Melanomas of the skin and eyes;
- Kaposi's sarcomas;
- Multiple myeloma;
- Other malignant tumors of various localizations.
Side effects
All adverse reactions associated with the use of laferobion, minor or moderate, usually disappear after treatment.
General disorders: when Laferobion is administered, flu-like symptoms are possible: chills, increased body temperature, fatigue, lethargy, as well as headache, muscle pain, joint pain, increased sweating; rarely - vomiting, dizziness, hot flashes. Hypersensitivity reactions to the drug may occur.
Disorders of the hematopoietic system: with prolonged use, leukopenia, thrombocytopenia, anemia, and nosebleeds are possible.
Gastrointestinal and liver disorders: increased levels of ALT and AST, alkaline phosphatase, loss of appetite, impaired liver function.
Endocrine disorders: thyroid dysfunction.
Disorders of the central and peripheral nervous system: with prolonged use, dizziness, sleep disturbance, confusion, anxiety and depression, increased excitability, drowsiness, ataxia, and paresthesia are possible.
Cardiovascular system disorders: possible hypertension or hypotension; rarely - tachycardia.
Disorders of the skin and subcutaneous tissues: allergic reactions, including rash (including herpetic), itching, hyperemia.
Respiratory system disorders: cough.
Other: changes at the injection site, visual impairment, renal dysfunction, electrolyte imbalance.
special instructions
Treatment with laferobion should be carried out under medical supervision.
With long-term use of the drug, a general blood count, liver, kidney and thyroid function are monitored.
All patients, before starting and regularly during treatment, are recommended to undergo a detailed analysis of peripheral blood, with mandatory qualitative and quantitative examination of blood parameters, as well as a biochemical blood test, including determination of electrolytes, calcium, liver enzymes and creatinine.
In all patients receiving the drug, it is recommended to carefully monitor plasma albumin levels and prothrombin time.
Prescribe the drug with caution if you have a history of diseases such as diabetes mellitus with episodes of ketoacidosis and COPD, bleeding disorders (including pulmonary thrombophlebitis), and severe myelosuppression.
When treating with the drug, it is necessary to ensure adequate hydration of the body; If fever occurs, other causes of its occurrence should be excluded. It is recommended to use the drug against the background of antihistamine and antipyretic therapy.
The development of severe and moderate side effects requires dose adjustment, and in some cases, discontinuation of treatment.
Stop using the drug in the following cases: prolongation of blood clotting time (in patients with chronic hepatitis), manifestations of pulmonary syndrome and X-ray detection of infiltrate or impaired pulmonary function, appearance or increase in the severity of visual impairment, impaired thyroid function (abnormal TSH level), decreased plasma albumin levels and a decrease in prothrombin time.
If an immediate hypersensitivity reaction develops (urticaria, angioedema, bronchospasm, anaphylaxis), the drug should be immediately discontinued and appropriate measures taken.
After the expiration date, the use of the drug is unacceptable. The drug is not subject to repeated quality control and extension of the shelf life after its expiration.
Use during pregnancy and lactation. There are no data on the use of the drug during pregnancy and lactation.
Children. Used in pediatric practice (see APPLICATION).
The ability to influence reaction speed when driving vehicles or working with other mechanisms. Some adverse CNS effects associated with the use of the drug may affect the ability of patients to drive vehicles and operate potentially dangerous machinery.
Directions for use and dosage
Laferobion nasal solution is used in the form of a spray, inhalation or by regular instillation into the nasal passages.
The recommended dose for instillation is 5 drops (or 0.25 ml) of a drug with an activity of 50,000-100,000 IU in each nostril. Laferobion is instilled every 1-1.5 hours, but not less than six times a day. The minimum duration of treatment is 2-3 days.
For one inhalation, 3 bottles of powder should be dissolved in 5 ml of boiled or sterile water. Inhalations are carried out through the nose and/or mouth twice a day.
In children under 1 month of age, use nasal turundas soaked in a nasal solution of the drug Laferobion. Turundas are injected into each nasal passage alternately for 10-15 minutes. For nasal instillation in children of this age group, it is recommended to use Laferobion with an activity of 50,000 IU in a dose of 2-3 drops in each nostril. The frequency of instillation is 4-6 times a day, the duration of treatment is 3-5 days.
To prevent acute respiratory viral infections during epidemics or in contact with a sick person, Laferobion 50,000-100,000 IU is used. The solution is instilled or sprayed 2 times a day, 5 drops (0.25 ml) with an interval of at least 6 hours. The drug is used throughout the entire period of existence of the threat of infection.
To obtain Laferobion with an activity of 50,000 IU, the contents of the bottle are dissolved in 2 ml of boiled or distilled water, with an activity of 100,000 IU - in 1 ml of water. To ensure that the solution is homogeneous, you must shake the bottle thoroughly.
The injection solution is used subcutaneously and intramuscularly. To prepare the solution, the contents of one bottle are dissolved in 1 ml of water for injection.
Recommended doses and treatment regimens:
- Acute hepatitis B (severe and moderate): the first 5-6 days - 1 million IU twice a day; the next 5 days - 1 million IU once a day. If longer treatment is necessary, the drug is administered twice a week, 1 million IU for 14 days. Laferobion is most effective in the first five days of the icteric period. With the development of hepatic coma and cholestatic hepatitis, the use of the drug is not recommended;
- Chronic hepatitis B (active): 3-6 million IU three times a week. Duration of treatment is up to 24 weeks. If at 12 weeks of therapy there is no decrease in the HbeAg titer and clinical improvement, treatment with the drug must be discontinued;
- Chronic hepatitis C: 3 million IU three times a week. Duration of treatment is up to 24 weeks. After 4 weeks of use, it is necessary to evaluate the level of the alanine aminotransferase enzyme and, if it is less than 50% of the initial level, the dose of Laferobion should be increased to 6 million IU. If there are no biochemical and clinical improvements at week 12, treatment with the drug should be discontinued;
- Tick-borne encephalitis: 1-3 million IU twice a day for 10 days. Maintenance therapy – 1-3 million IU once every 2 days for 10 days;
- Chronic myeloid leukemia: 9 million IU every day until hematological remission is achieved. Maintenance dose – 9 million IU three times a week;
- Lymphocytic (hairy cell) leukemia: 3 million IU every day until hematological remission is achieved. Maintenance dose – 3 million IU three times a week;
- Renal cell carcinoma: 18 million IU three times a week;
- Malignant melanoma: 18 million IU every day until partial or complete regression of metastases is achieved. Maintenance dose – 18 million IU three times a week;
- Kaposi's sarcoma and AIDS (acquired immunodeficiency syndrome): 36 million IU every day for a long time. Cancellation of Laferobion is possible in case of intolerance to the components of the drug or in case of uncontrolled progression of the disease. Maintenance therapy (after stabilization of the condition) - 18 million IU three times a week.
For oncological diseases, the drug is also used after regression of the tumor focus or achievement of remission, since Laferobion has only a cytostatic effect, preventing the mitotic division of tumor cells.
Interactions
The drug should be used with caution simultaneously with opioid drugs, analgesics, hypnotics and sedatives (potentially causing a myelosuppressive effect).
When used simultaneously with drugs that are metabolized by oxidation (including xanthine derivatives - aminophylline and theophylline), the possibility of Laferobion's influence on oxidative metabolic processes should be taken into account. The concentration of theophylline in blood plasma must be monitored and, if necessary, the dosage regimen must be adjusted.
When using the drug in combination with chemotherapeutic drugs (cytarabine, doxorubicin, teniposide, cyclophosphamide), the risk of developing life-threatening toxic effects (their severity and duration) increases.
When used simultaneously with zidovudine, the risk of developing neutropenia increases.
Note!
Description of the drug Laferobion supp. 150 thousand ME No. 10 on this page is a simplified author’s version of the apteka911 website, created on the basis of the instructions for use.
Before purchasing or using the drug, you should consult your doctor and read the manufacturer's original instructions (attached to each package of the drug). Information about the drug is provided for informational purposes only and should not be used as a guide to self-medication. Only a doctor can decide to prescribe the drug, as well as determine the dose and methods of its use.
